Selected breast cancer highlights from the ASCO 2012

被引：0

作者：

Petru E. ^{[1
]}

Weiss E.-C. ^{[1
]}

机构：

[1] Clinical Department, University Hospital for Gynecology, 8036 Graz

来源：

memo - Magazine of European Medical Oncology | 2013年 / 6卷 / 1期

关键词：

Bisphosphonates; HER2 receptor status; Hormone-receptor status; Ki-67; Osteoporosis; Parenteral nutrition;

D O I：

10.1007/s12254-012-0067-3

中图分类号：

学科分类号：

摘要：

The abstracts are a selection of clinically relevant papers presented at the American Society of Clinical Oncology (ASCO) 2012. The results of the EMILIA study were a milestone presented at the meeting. A total of 991 patients with metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer had been pretreated with a taxane and trastuzumab. They were randomized into two groups: Trastuzumab emtansine conjugate (T-DM1) or capecitabine- lapatinib. Significant differences were found with regard to progression-free survival and the two-year overall survival. Another study analyzed the relevance of the hormone-receptor (HR) status for the prognosis of patients with operable HER2-overexpressing breast cancer. A significant difference in the risk of the development of brain metastases was found depending on the HR status. In the MA.27 study, patients received adjuvant therapy with aromatase inhibitors. A significant proportion of cases reported therapy of osteoporosis, mainly with bisphosphonates. Osteoporosis therapy influenced recurrence-free survival. In another study, the prognostic influence of Ki-67 was evaluated before and after neoadjuvant chemotherapy with TAC (docetaxel/doxorubicin/cyclophosphamide). A metaanalysis analyzed the possible discordance between the HR status and the HER2 status in the primary tumor as compared to metastasis in 2,806 breast cancer patients. The estrogen-receptor (ER)-, and the progesterone-receptor (PR) status as well as the HER2 status changed in a significant proportion of cases. Parenteral nutrition in 129 terminal oncological patients with progressive cancer was investigated within a randomized placebo-controlled trial. They either received one liter of 0.9 % physiological saline subcutaneously or placebo. Survival, symptoms of dehydration, and quality of life were analyzed. © 2013 Springer-Verlag Wien.

引用

页码：29 / 31

页数：2

共 6 条

[1]

Blackwell K., Miles D., Gianni L., Krop I., Welslau M., Baselga J., Pegram M., Oh D., Dieras V., Olsen S., Fang L., Lu M., Guardino E., Verma S., Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane, J Clin Oncol., 30, SUPPL., (2012)

[2]

Vaz Duarte L., Et al., Impact of hormone receptor status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients with human epidermal growth factor receptor-2 positive (HER2) breast cancer in the National comprehensive cancer network (NCCN), J Clin Oncol., 30, SUPPL., (2012)

[3]

Shepherd E., Chapman J., Ali S., Zhu L., Leitzel K., Goss P., Lipton A., Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrazole, NCIC CTG MA.27. J Clin Oncol., SUPPL., (2012)

[4]

Von Minckwitz G., Mueller B., Blohmer J., Kaufmann M., Eidtmann H., Eiermann W., Gerber B., Tesch H., Hilfrich J., Huober J., Fehm T., Barinoff J., Jackisch C., Prinzler J., Ruediger T., Erbstoesser E., Loibl S., Denkert C., Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial, J Clin Oncol., 30, SUPPL., (2012)

[5]

Aurilio G., Disalvatore D., Bagnardi V., Munzone E., Adamoli L., Curigliano G., Pruneri G., Sciandivasci A., De Vita F., Goldhirsch A., Nole F., A meta-analysis of receptor status discordance between primary breast cancer and metastases, J Clin Oncol., 30, SUPPL., (2012)

[6]

Dalal S., Hui D., Torres-Vigil I., Palmer L., Allo J., Frisbee-Hume S., Tarleton K., Bruera E., Parenteral hydration in advanced cancer patients: A multi-center, double-blind, placebo-controlled randomized trial, J Clin Oncol., 30, SUPPL., (2012)

← 1 →